Pyxis Oncology (PYXS) Stock Forecast & Price Target

Pyxis Oncology is attractive because MICVO has shown a 36% confirmed objective response rate and 94% disease control in a heavily pretreated 2L+ HNSCC population, with responses occurring quickly and consistently across HPV-positive, HPV-unrelated, EGFRi-pretreated, and taxane-exposed subgroups. The dose-capping protocol materially improved the risk profile, cutting treatment-related discontinuations to 14.3% and reducing grade 3 peripheral neuropathy to 17.1% without a clear efficacy trade-off, which strengthens confidence in its therapeutic window. Fundamentally, the company’s EDB+FN tumor-microenvironment targeting strategy, early survival signal with median PFS of 6.2 months and median OS not reached, and upcoming Phase 3 development in a large unmet-need market support a constructive outlook.

Pyxis Oncology is viewed negatively because its valuation depends heavily on MICVO, and the company faces material clinical and regulatory risk if the asset fails to demonstrate efficacy or triggers safety concerns that halt development. The business also has a meaningful commercial overhang, since MICVO may struggle against current and future therapies, limiting adoption even if development progresses. In addition, an inability to achieve sales estimates would undermine financial expectations and weaken confidence in the company’s long-term fundamentals.